UCB SA ADR UCBJY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if UCBJY is a good fit for your portfolio.
News
-
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
-
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
-
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
-
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
-
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
-
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
-
NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
-
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Trading Information
- Previous Close Price
- $38.86
- Day Range
- $40.19–40.54
- 52-Week Range
- $34.85–48.45
- Bid/Ask
- $39.05 / $42.44
- Market Cap
- $15.37 Bil
- Volume/Avg
- 19,000 / 16,768
Key Statistics
- Price/Earnings (Normalized)
- 18.74
- Price/Sales
- 2.91
- Dividend Yield
- 1.81%
- Dividend Yield (Forward)
- 1.81%
- Total Yield
- 2.38%
Company Profile
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 8,703
- Website
- https://www.ucb.com
Competitors
Valuation
|
Metric
|
UCBJY
|
JAZZ
|
GMAB
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.74 | 9.18 | 23.60 |
Price/Book Value | 1.56 | 2.19 | 4.61 |
Price/Sales | 2.91 | 2.23 | 8.50 |
Price/Cash Flow | 14.39 | 6.87 | 22.70 |
Price/Earnings
UCBJY
JAZZ
GMAB
Financial Strength
|
Metric
|
UCBJY
|
JAZZ
|
GMAB
|
|---|---|---|---|
Quick Ratio | 0.77 | 1.41 | 11.36 |
Current Ratio | 1.13 | 2.06 | 11.38 |
Interest Coverage | 5.84 | 0.65 | 177.50 |
Quick Ratio
UCBJY
JAZZ
GMAB
Profitability
|
Metric
|
UCBJY
|
JAZZ
|
GMAB
|
|---|---|---|---|
Return on Assets (Normalized) | 4.60% | 9.37% | 17.79% |
Return on Equity (Normalized) | 8.10% | 31.71% | 19.98% |
Return on Invested Capital (Normalized) | 6.68% | 14.19% | 17.39% |
Return on Assets
UCBJY
JAZZ
GMAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jyfy | $454.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bhzgwp | $90.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kljvf | $89.7 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Rypbg | $40.2 Bil | |
MRNA
| Moderna Inc | Crsy | $30.5 Bil | |
ARGX
| argenx SE ADR | Lfhs | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Bwp | $23.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yhsrzm | $21.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nrngxcv | $17.8 Bil | |
INCY
| Incyte Corp | Yrptbnw | $12.3 Bil |